Position in ARVN
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$150,460
-$41,463 QoQ
Shares Held
18,106
0.0% QoQ
Ownership
0.028%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#119
of 201 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ARVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026INTECH INVESTMENT MANAGEMENT LLC holds $203,460,728 across 193 Biotechnology names. ARVN ranks #129 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
298,883 | $16,262,224 | |
| 2 | INCY |
Incyte Corp
|
141,278 | $16,015,273 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,260 | $13,879,999 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
162,292 | $12,702,594 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
36,760 | $11,065,862 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
20,520 | $10,192,899 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
37,384 | $9,008,422 | |
| 8 | TGTX |
Tg Therapeutics, Inc.
|
124,646 | $6,848,051 |
All Filings in ARVN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $150,460 | 18,106 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $191,923 | 18,106 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $381,571 | 32,173 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $278,203 | 32,653 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $232,046 | 31,528 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $326,486 | 46,508 | Shares | Sole | 2025-05-20 | |
| 2024-12-31 | $462,993 | 24,152 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $350,386 | 14,226 | Shares | Sole | 2024-11-08 | |
| No filing history on record for this holder in this stock. | ||||||